The Best Turnaround Stock to Invest $1,000 in Right Now

Bristol Myers Squibb and Pfizer are both trading well below recent highs—BMY about 35% off its 2022 peak and PFE roughly 55% below its 2021 high—primarily because each faces upcoming patent cliffs that threaten legacy drug revenues; management at both firms has been filling pipelines via acquisitions and licensing (Pfizer recently struck weight‑loss deals) but Pfizer’s moves signal a higher‑risk turnaround. Valuation and income metrics diverge: BMY trades at roughly 17x earnings with a ~4.8% yield and ~85% payout ratio, whereas Pfizer is near 15x with a 6.6% yield but a 100% payout ratio and a history of a dividend cut after the 2009 Wyeth acquisition, implying greater dividend risk. For institutional investors, BMY presents a more conservative income play, while Pfizer offers a lower valuation and larger upside if the turnaround succeeds, but with materially higher execution and dividend risk.

Analysis

Bristol Myers Squibb and Pfizer are being framed as contrasting turnaround opportunities: BMY is about 35% below its 2022 high while PFE is roughly 55% below its 2021 peak, and both face impending patent cliffs that threaten legacy drug revenues. Pfizer has recently pursued acquisitions and a licensing deal for a Chinese weight‑loss candidate to fill its pipeline after setbacks in developing an in‑house competitor, signalling active management intervention.

Valuation and income metrics diverge meaningfully: BMY trades at roughly 17x earnings with a ~4.8% dividend yield and an estimated ~85% payout ratio, whereas PFE trades near 15x with a ~6.6% yield and an estimated 100% payout ratio; Pfizer’s prior dividend cut after the Wyeth acquisition is cited as precedent for dividend vulnerability. The article positions BMY as the more conservative income play and PFE as the higher‑risk, higher‑return contrarian bet due to its larger drawdown and lower valuation.

Investment drivers to watch are clear and binary: successful M&A or new drug approvals could offset patent‑cliff revenue losses, while failed integrations, regulatory setbacks or sustained payout ratios near 100% would increase downside and dividend risk. Given mixed sentiment and limited near‑term market impact, the risk/reward favors selective exposure rather than blanket conviction in either name.

Key Decisions for Investors

• Income‑oriented investors should lean toward Bristol Myers Squibb given its 4.8% yield and lower perceived dividend risk versus Pfizer, but actively monitor the ~85% payout ratio and upcoming patent expirations as triggers to reduce exposure
• Contrarian or event‑driven investors may allocate a smaller, opportunistic position to Pfizer because of its ~55% decline and lower 15x valuation, but size positions conservatively and require evidence of successful pipeline fills or cash‑flow improvement before increasing exposure
• Avoid buying Pfizer solely for yield given the ~100% payout ratio and the company’s history of a dividend cut; treat the 6.6% yield as conditional on execution and regulatory outcomes
• Track near‑term catalysts—patent cliff timelines, outcomes of Pfizer’s weight‑loss licensing and acquisition integrations, and any dividend policy commentary—and rebalance positions when clear clinical/regulatory or cash‑flow evidence emerges